Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.
Editorial Material
Immunology
David H. Canaday et al.
Summary: After receiving the BNT162b2 messenger RNA vaccine, nursing home residents had antibody neutralization titers one-quarter of healthcare workers who were naive to SARS-CoV-2.
CLINICAL INFECTIOUS DISEASES
(2021)
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Microbiology
Chihiro Motozono et al.
Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Review
Virology
Ivana Lazarevic et al.
Summary: Although SARS-CoV-2 evolves slowly compared to other RNA viruses, its rapid transmission during the COVID-19 pandemic has led to the emergence of numerous variants, some of which have been labeled as variants of concern. These variants may have an impact on transmission, morbidity/mortality, and evasion of neutralization by antibodies, especially monoclonal antibodies.
Article
Microbiology
Takuya Tada et al.
Summary: Convalescent-phase sera and antibodies elicited by Pfizer BNT162b2 vaccination can still neutralize several SARS-CoV-2 variants effectively, while Regeneron monoclonal antibodies may be less effective against certain variants, suggesting the need for continued surveillance for potential new variants.
Article
Microbiology
Yosuke Hirotsu et al.
Summary: A study revealed the emergence of a novel coronavirus lineage with multiple mutations in Japan, including potential escape mutations in the spike protein. This lineage has been spreading in Japan since early 2021 and requires ongoing monitoring for global implications.
Article
Medicine, General & Internal
Lu Lu et al.
Summary: The study demonstrates that the N501Y mutation has a significant impact on neutralizing activity of COVID-19 convalescent sera and anti-RBD IgG assays. Patients infected with N501Y variants may exhibit reduced antibody binding and lower positivity rates in IgG assays.
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Multidisciplinary Sciences
Shutoku Matsuyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
Alina Baum et al.
Review
Multidisciplinary Sciences
Florian Krammer
